Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers
Executive Summary
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.
You may also be interested in...
Manufacturer Restrictions On 340B Discounts Cut Contract Pharmacy-Based Savings 23% Or More
Hospital survey seeks to determine the financial impact of manufacturer limits on the 340B discounts they provide on drugs dispensed through pharmacies acting under contract with the program's covered entities.
340B Dispute Resolution Process On Ice As Feuds Between Pharma, Providers, HHS Heat Up
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
340B And US Drug Pricing: Trump’s First Target Is One That Lasts
The US government program that allows safety net providers to purchase drugs at deep discounts is probably not what most American voters have in mind when they say drug pricing is a top issue. But the 340B program has been a rare area of consistent focus – and actual sustained change – in the Trump Administration.